KOCSMÁR, Ildikó, KOCSMÁR, Éva, PAJOR, Gábor, KULKA, Janina, SZÉKELY, Eszter, KRISTIANSEN, Glen, SCHILLING, Oliver, NYIRÁDY, Péter, KISS, András, SCHAFF, Zsuzsa, RIESZ, Péter und LOTZ, Gábor, 2022. Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer. Freiburg: Universität.
Elsevier - Harvard (with titles)Kocsmár, I., Kocsmár, Éva, Pajor, G., Kulka, J., Székely, E., Kristiansen, G., Schilling, O., Nyirády, P., Kiss, A., Schaff, Z., Riesz, P., Lotz, G., 2022. Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer. Universität, Freiburg. https://doi.org/10.3390/cancers14194570
American Psychological Association 7th editionKocsmár, I., Kocsmár, Éva, Pajor, G., Kulka, J., Székely, E., Kristiansen, G., Schilling, O., Nyirády, P., Kiss, A., Schaff, Z., Riesz, P., & Lotz, G. (ca. 2022). Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer [Cd]. Universität. https://doi.org/10.3390/cancers14194570
Springer - Basic (author-date)Kocsmár I, Kocsmár Éva, Pajor G, Kulka J, Székely E, Kristiansen G, Schilling O, Nyirády P, Kiss A, Schaff Z, Riesz P, Lotz G (2022) Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Kocsmár, Ildikó/ Kocsmár, Éva/ Pajor, Gábor/ Kulka, Janina/ Székely, Eszter/ Kristiansen, Glen/ Schilling, Oliver/ Nyirády, Péter/ Kiss, András/ Schaff, Zsuzsa/ Riesz, Péter/ Lotz, Gábor, Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer, Freiburg 2022.